C4 Therapeutics, Inc. Operating Lease Right-of-Use Assets
C4 Therapeutics, Inc. (CCCC) had Operating Lease Right-of-Use Assets of $37.64 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-11
- 2026-06-30: Operating Lease, Right-of-Use Asset $37.64M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $39.09M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $40.53M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $41.96M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $37.64M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $39.09M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $40.53M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $41.96M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $54.22M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $55.89M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $57.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | $59.17M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $60.78M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $62.38M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $63.96M 10-K · filed 2025-02-27 |
| 2023-09-30 | $65.52M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $67.07M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $68.60M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $70.12M 10-K · filed 2024-02-22 |
| 2022-09-30 | $71.62M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $73.12M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $74.83M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $31.95M 10-K · filed 2023-02-23 |
| 2021-09-30 | $12.25M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $12.58M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $12.91M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $13.23M 10-K · filed 2022-02-24 |
| 2020-09-30 | $13.54M 10-Q · filed 2020-11-12 |
| 2019-12-31 | $14.45M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |